Some recent client engagements and the tangible benefits realized from working with Diaceutics – including where possible the return on their investment in the diagnostic and Diaceutics – are described in our anonymized case studies below.

Partnering Optimization
Diaceutics assisted Client in decision to avoid partnering with a major oncology diagnostic company after Diaceutics provided a better understanding of the conflicting strategic goals and hidden risks in the company. Based on Diaceutics research on alternative partners, the Client engaged with a new, commercially aligned diagnostic partner saving an immediate $16 million. Furthermore, the benefits of this new partnership are targeted to enable an additional $388 million above forecasts in the first two years after launch.
Implementation of Rapid Deployment Diagnostic Model
Based on Diaceutics suggestions to leverage a rapid deployment diagnostic model, Client relaunched a major oncology drug with a first line patient, target indication in the EU estimated to generate an additional $157 million in the first year alone. This established the program as a model in patient/doctor centered communication.

In order to avoid significant risk to their leadership position in infectio*us disease, Diaceutics worked with Client to design and launch a multi-million dollar, 300-person strong PM clinical trial initiative to stem significant loss of market share. This effort, lauded by the FDA, generated an additional $30 million in U.S. revenue within 5 months.
Redesigning Strategic Personalized Medicine Focus
Working closely with Diaceutics as a strategic PM partner, Client moved from running PM as a fragmented, technologically embedded activity to seeing PM as a holistic market-based asset, able to facilitate greater integration in customer and R&D relationships.
Rescue Strategy
Client had launched a new HIV indication into the market but a poorly designed diagnostic program and loose control over the diagnostic partner resulted in less than 1/6 of anticipated revenues for the drug in Year 1 alone. Diaceutics assisted client in designing a multi partner diagnostic “rescue strategy” in order to reposition the therapy.
Ensuring Manufacturing Capabilities
At the request of Client, Diaceutics performed audit of manufacturing capability of US-based diagnostic company to assess quality and capacity for successful development and commercial launch of companion diagnostic to product entering Phase III trials. The audit process was used by Client to determine critical failure risks and identify alternative strategies to manage those manufacturing risks.
Revising Companion Diagnostic Approach
Diaceutics was hired by Client to assist in revamping companion diagnostic strategy, including the assessment of future risks to supply chain through capacity and logistical problems of maintaining relationship with diagnostic partner. Results were used to generate multiple sources of high quality companion diagnostics in US, EU and RoW (rest of world).

In today’s challenging economy, no industry can afford to invest time and resources without some clear indication of the likely return on those investments. And like every other high cost, high-pressure industry, the pharmaceutical industry requires clear analytics and functional metrics to provide hard evidence of the value of its investments.

With a clear understanding of our clients' needs and the benefit at the pharmaceutical development team level to provide clear justification to management for investing resource on companion diagnostics, Diaceutics tracks and provides hard evidence of the value of these investments. Including, where possible, the value of investing with Diaceutics. To date, Diaceutics has delivered on average greater than a $100 return for every $1 invested in leveraging the Diaceutics process and approach to PM strategy and planning.

Broadening Thought on Companion Diagnostics
Diaceutics encouraged ovarian cancer team to broaden their thinking about what a “companion diagnostic” test could be and assisted client in researching and designing a multi-test approach that increased the patient reservoir presenting for therapy four fold and enabled an earlier first line indication. This multi-test approach, rather than a single strictly “companion diagnostic” approach, Diaceutics improved client’s probability of achieving therapy forecasts from 40% to 80%.

Similarly, Diaceutics encouraged an Alzheimer’s team to broaden their thinking about diagnostic tests to enable an earlier disease indication, allowing for a 4 fold increase in the patient reservoir presenting for new Alzheimer’s therapy. Again, using a multi-test approach, rather than a single strictly “companion diagnostic” approach, Diaceutics improved client’s probability of achieving therapy forecasts from 25% to 90%.